Somi Igbene, PhD,  science writer—

Combining Xcopri (cenobamate) with existing antiseizure medications may significantly reduce the frequency of seizures in adults with Dravet syndrome, according to a report of four patients. The oral medication — marketed as Ontozry in Europe — reduced the frequency of seizures in all four adults by…

ReS3-T, an investigational medicine developed by reMynd for therapy-resistant epilepsies such as Dravet syndrome, has been accepted into the National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). The ETSP identifies potential therapies for drug-resistant epilepsy and disease prevention and modification by allowing researchers…